A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer

The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer

Inclusion Criteria:

• Provision of written informed consent
• Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2
• Histologically or cytologically conformed non-small cell lung cancer
• Aged 18 or over

Exclusion Criteria:

• Previous thoracic radiotherapy
• Any condition that may pre-dispose the patient to suffer an individual drug-relaged DLT (dose limiting toxicity) event
• Known hypersensitivity to any component of study medication